CRIS Earnings Prediction
The chart below shows how CRIS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRIS sees a +8.73% change in stock price 10 days leading up to the earnings, and a -4.17% change 10 days following the report. On the earnings day itself, the stock moves by -1.81%. This data can give you a slight idea of what to expect for the next quarter's release.
CRIS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.93M
3.46%
15.12%
Gross Margin
104.37%
37.27%
4.54%
Operating Margin
-355.41%
-22.47%
-27.63%
Net Margin
-344.32%
-19.92%
-25.73%
EPS
-1.70
-20.19%
-16.26%
No Data Available
CRIS Earnings Analysis
Curis Inc Corporation (CRIS.O) Earnings Conference Call
Positive
Net Loss Improvement: Curis reported a net loss of $10.1 million or $1.70 per share for the third quarter of 2024 compared to a net loss of $12.2 million or $2.13 per share for the same period in 2023, indicating improved financial performance.
R&D Expense Reduction: Research and development expenses were $9.7 million for the third quarter of 2024 compared to $10.4 million for the same period in 2023, reflecting effective cost management.
Decrease in Administrative Expenses: General and administrative expenses were $3.8 million for the third quarter of 2024 compared to $4.8 million for the same period in 2023, showing a decrease in operational costs.
Financial Position Enhancement: Curis completed a registered direct offering and concurrent private placement of unregistered warrants with net proceeds of approximately $10.8 million, enhancing its financial position.
Financial Runway Assurance: Curis expects its existing cash and cash equivalents will enable its planned operations into mid-2025, providing a solid financial runway for ongoing projects.
Negative
Quarterly Net Loss Comparison: Curis reported a net loss of $10.1 million or $1.70 per share for the third quarter of 2024 compared to a net loss of $12.2 million or $2.13 per share for the same period in 2023.
Net Loss Comparison: Curis reported a net loss of $33.8 million or $5.77 per share for the nine months ended September 30, 2024, compared to a net loss of $35.7 million or $6.96 per share for the same period in 2023.
R&D Expense Decrease: Research and development expenses were $9.7 million for the third quarter of 2024 compared to $10.4 million for the same period in 2023, indicating a decrease attributed to lower consulting and employee-related costs.
Administrative Expense Reduction: General and administrative expenses were $3.8 million for the third quarter of 2024 compared to $4.8 million for the same period in 2023, reflecting a decrease primarily due to lower legal and employee-related costs.
G&A Expense Decrease: G&A expenses were $13.4 million for the nine months ended September 30, 2024, compared to $13.8 million for the same period in 2023, showing a slight decrease.
CRIS FAQs
How does CRIS typically perform around its earnings report dates?
Is Curis, Inc. (CRIS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CRIS Earning Call Sentiment
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CRIS.O
-4.98%Positive
The earnings call summary reveals a mix of financial challenges and strategic progress. Key points include improved net loss figures, ongoing regulatory discussions, and a positive outlook on emavusertib's potential in various studies. The Q&A session highlights management's proactive engagement with the FDA and optimism about market opportunities. Despite financial risks and a competitive landscape, the company's strategic focus and recent fundraising efforts suggest a positive sentiment. Overall, these factors, combined with the recent fundraising, are likely to result in a stock price increase of 2% to 8%.